Clinical Trials Logo

Pulmonary Fibrosis clinical trials

View clinical trials related to Pulmonary Fibrosis.

Filter by:

NCT ID: NCT03535545 Recruiting - Lung Cancer Clinical Trials

Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

The goal of this study is to investigate the safety of [68Ga]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.

NCT ID: NCT03508375 Recruiting - Clinical trials for Systemic Scleroderma

Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis

SCLEROLUNG
Start date: May 15, 2018
Phase: N/A
Study type: Interventional

Systemic Scleroderma (SCS) is an autoimmune disease characterized by vascular involvement, a dysimmune condition, cutaneous and visceral fibrosis. Interstitial lung disease (ILD) affects 75% of SSc patients and is the leading cause of death in SSc. No diagnostic or prognostic biomarkers of SSc-associated ILD have been validated to date. The search for such a serum biomarker is essential to assess the severity of these patients and to help the therapeutic management. We have shown that soluble fractalkine is elevated in SSc patients, especially in SSc patients with ILD. The fractalkine is both an endothelial adhesion molecule and a chemokine that binds to the CX3CR1 receptor expressed by immune populations. It would thus reflect the vasculopathy and inflammation that lead to the fibrosing pulmonary involvement of this disease. Objectives and means: We aim to perform a low-risk interventional biomedical research which main objective is the quantitative evaluation of soluble fractalkine in SSc patients with ILD in comparison with SSc patients without ILD. This epidemiological, explanatory, analytical, single-center study will comprise three groups: 1 / SSc without ILD (control group in the context of SSc), 2/ SSc with ILD and 3/ patients with idiopathic pulmonary fibrosis (IPF) (control group of the ILD). Secondary objectives are evaluation of: 1 / fractalkine levels in the IPF, 2 / correlations between fractalkine levels and severity of ILD and of SSc disease over time, 3 / correlations between fractalkine and 2 other biomarkers: KL-6 (marker of pulmonary fibrosis) and soluble CD146 (sCD146, marker of vasculopathy), 4 / predictive values of the decline in lung function of these 3 markers.

NCT ID: NCT03503188 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Digital Auscultation Test - IPF Data Collection

Start date: March 28, 2018
Phase: Phase 4
Study type: Interventional

The aim of this study is the data collection for patients with IPF and symptom matched controls to create a database of lung auscultation sounds and basic patient characteristics.

NCT ID: NCT03502902 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

Start date: April 26, 2018
Phase: Phase 1
Study type: Interventional

A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female Subjects

NCT ID: NCT03500731 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Start date: April 19, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.

NCT ID: NCT03499275 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Muscle Stimulation in Advanced Idiopathic Pulmonary Fibrosis

MUST-IPF
Start date: October 15, 2018
Phase: N/A
Study type: Interventional

The aims of this study are to determine whether neuromuscular stimulation (NMES) of the quadriceps muscle is acceptable to patients with Idiopathic Pulmonary Fibrosis (IPF) and staff and whether it can impact clinical and healthcare resource usage outcomes. .

NCT ID: NCT03486262 Enrolling by invitation - Clinical trials for Lung Cancer and Idiopathic Pulmonary Fibrosis

Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization

K-FPI
Start date: February 1, 2018
Phase:
Study type: Observational

Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers. The cases are recovered retrospectively from the records of the pulmonology and pathology departments of our various partners.

NCT ID: NCT03480451 Terminated - Clinical trials for Idiopathic Pulmonary Fibrosis

Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis

IPF
Start date: September 12, 2017
Phase: N/A
Study type: Interventional

Idiopathic pulmonary fibrosis (IPF), a chronic fibrotic lung disease of unknown cause, is characterized by relentless progression, with a three-year mortality of up to 50%. IPF has high morbidity, with 90% of patients reporting dyspnea at the time of diagnosis and this is strongly correlated with quality of life and mortality. As IPF progress, breathlessness worsens, physical functional capacity declines, and health-related quality of life deteriorates. Pulmonary rehabilitation (PR) can improve well-being in patients with other chronic lung disease, but little is known regarding PR in IPF.

NCT ID: NCT03478553 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis (IPF)

The Genetics of Pulmonary Fibrosis

Start date: January 18, 2018
Phase:
Study type: Observational

This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.

NCT ID: NCT03477526 Terminated - Clinical trials for Idiopathic Pulmonary Fibrosis and COPD

Status and Develepment Mental Quality of Life COPD/IPF Inpatients Before and After Pulmonary Rehabilitation

Start date: February 26, 2019
Phase: N/A
Study type: Interventional

As the result of our last study "Long Term effects of an Inpatient Pulmonary Program in Patients with Pulmonary Fibrosis" already demonstrated the positive effects of a Pulmonary Rehabiliation on the mental status. In this current study the aim will be to analyse the personality type regarding anxiety and depression